Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ

• Published in: British journal of cancer 2005-05, Vol.92 (9), p.1720-1728
• Main Authors: Wülfing, P, Kersting, C, Buerger, H, Mattsson, B, Mesters, R, Gustmann, C, Hinrichs, B, Tio, J, Böcker, W, Kiesel, L
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Angiogenesis; Biological and medical sciences; Biomarkers - analysis; Biomedical and Life Sciences; Biomedicine; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer Research; Carcinoma in Situ - metabolism; Carcinoma in Situ - pathology; Carcinoma, Ductal, Breast - metabolism; Carcinoma, Ductal, Breast - pathology; Drug Resistance; Endothelin-1 - metabolism; Epidemiology; Female; Fibroblast Growth Factor 2 - metabolism; Fibroblasts; Gynecology. Andrology. Obstetrics; Humans; Kinases; Mammary gland diseases; Medical research; Medical sciences; Metastasis; Middle Aged; Molecular Diagnostics; Molecular Medicine; Oncology; Protein Array Analysis; Receptor Protein-Tyrosine Kinases - metabolism; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Fibroblast Growth Factor - metabolism; Receptors, Vascular Endothelial Growth Factor - metabolism; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism; Vascular Endothelial Growth Factor C - metabolism; Vascular Endothelial Growth Factor Receptor-1 - metabolism; Vascular Endothelial Growth Factor Receptor-2 - metabolism
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/sj.bjc.6602567

The objective of this study was to investigate expression of various growth factors associated with angiogenesis and lymphangiogenesis and of their receptors in ductal carcinomas in situ of the breast (DCIS). We studied protein expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF)-A, endothelin (ET)-1, and VEGF-C, and their receptors bFGF-R1, Flt-1, KDR, ET A R, ET B R, and Flt-4 immunohistochemically in 200 DCIS ( pure DCIS: n =96; DCIS adjacent to an invasive component: n =104) using self-constructed tissue microarrays. Basic fibroblast growth factor-R1, VEGF-C, Flt-4, and ET A R were expressed in the tumour cells in the majority of cases, whereas bFGF and Flt-1 expression was rarely observed. VEGF-A, KDR, ET-1, and ET B R were variably expressed. The findings of VEGF-C and its receptor Flt-4 as lymphangiogenic factors being expressed in tumour cells of nearly all DCIS lesions and the observed expression of various angiogenic growth factors in most DCIS suggest that in situ carcinomas are capable of inducing angiogenesis and lymphangiogenesis. Moreover, we found a higher angiogenic activity in pure DCIS as compared to DCIS with concomitant invasive carcinoma. This association of angiogenic factors with pure DCIS was considerably more pronounced in the subgroup of non-high-grade DCIS ( n =103) as compared with high-grade DCIS ( n =94). Determination of these angiogenic markers may therefore facilitate discrimination between biologically different subgroups of DCIS and could help to identify a particularly angiogenic subset with a potentially higher probability of recurrence or of progression to invasiveness. For these DCIS, targeting angiogenesis may represent a feasible therapeutic approach for prevention of progression of DCIS to invasion.